Viral vaccines

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7374768
SERIAL NO

08459040

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A mutant virus for use as a vaccine for prophylaxis or therapy, wherein the genome of the virus is defective in respect of a gene essential for the production of infectious virus. In one aspect the mutant virus, e.g. a herpesvirus, e.g HSV-1 or HSV-2, is capable of protecting a susceptible species immunised therewith against infection by the corresponding wild-type virus. In another aspect, the mutant virus acts as a vector for an immunogenic protein derived from a pathogen, encoded by foreign DNA incorporated in the mutant virus. The mutant virus can be produced by a recombinant host cell which expresses a gene complementing the defect. The mutant virus can be infectious for the host to be protected, and the genetic defect can allow expression in the infected host of at least some of the viral genes, which can provoke a cell-mediated immune response. The defect can be in a glycoprotein gene such as gH.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
XENOVA RESEARCH LIMITED310 CAMBRIDGE SCIENCE PARK MILTON ROAD CAMBRIDGE

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Boursnell, Michael Edward Griffith Cambridge, GB 6 53
Inglis, Stephen Charles Linton, GB 6 53
Minson, Anthony Charles Great Shelford, GB 4 44

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation